Press releases
- InDex Pharmaceuticals Holding AB (publ) interim report January – September 201927 November 2019 - Regulatory press release
- InDex Pharmaceuticals presents at Redeye Life Science Day and Avanza Börsdag November 19, 201918 November 2019 - Other press release
- InDex Pharmaceuticals Holding AB (publ) announces Nomination Committee for the 2020 Annual General Meeting01 November 2019 - Other press release
Cobitolimod
Cobitolimod (Kappaproct, DIMS0150) is a potential new medication for patients with moderate to severe active ulcerative colitis.
Cobitolimod is a first in class treatment that provides a local anti-inflammatory effect which in clinical trials has shown to result in significant improvements of the major clinical symptoms.
Cobitolimod has very limited systemic absorption. This gives the drug a favorable safety profile, in sharp contrast to many approved treatments.
Learn moreCalender
- 20 February 2020Interim report Q4
- 3 March 2020Presentation at Carnegie Healthcare Seminar
- 30 March 2020Annual Report
- 20 April 2020Annual General Meeting
- 7 May 2020Interim report Q1
- 26 August 2020Interim report Q2
- 25 November 2020Interim report Q3
